Chemours Co Stock Today

CC Stock  USD 21.82  0.10  0.46%   

Performance

6 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 32

 
High
 
Low
Below Average
Chemours is trading at 21.82 as of the 28th of November 2024, a 0.46% down since the beginning of the trading day. The stock's open price was 21.92. Chemours has about a 32 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Note, on September 5, 2023, Representative Michael C Burgess of US Congress acquired $15k to $50k worth of Chemours's common stock.
Business Domain
Materials
IPO Date
1st of July 2015
Category
Basic Materials
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware. Chemours operates under Specialty Chemicals classification in the United States and is traded on New York Stock Exchange. The company has 149.41 M outstanding shares of which 7.28 M shares are currently sold short in the market by investors with about 4.18 days to cover all shorted shares. More on Chemours Co
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Chemours Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEOMark Vergnano
Thematic Ideas
Showing 3 out of 6 themes
Old NameCredit Industriel et Commercial SA
Business ConcentrationDiversified Chemicals, Specialty Chemicals, Basic Materials, NYSE Composite, SP Midcap 400, Synthetics, Plastics, Chemicals Makers, Chemicals, SRI Sustainable Growth, Trump Equities, Materials, Chemicals, Specialty Chemicals, Basic Materials (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover1.020.7305
Significantly Up
Slightly volatile
Gross Profit Margin0.260.2167
Fairly Up
Slightly volatile
Net Debt2.4 B3.1 B
Way Down
Slightly volatile
Total Current Liabilities1.8 B2.5 B
Way Down
Slightly volatile
Non Current Liabilities Total4.1 BB
Significantly Down
Slightly volatile
Total Assets7.5 B8.3 B
Moderately Down
Slightly volatile
Total Current AssetsB3.8 B
Significantly Down
Slightly volatile
Total Cash From Operating Activities635.8 M556 M
Fairly Up
Slightly volatile
Debt Levels
Chemours can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Chemours' financial leverage. It provides some insight into what part of Chemours' total assets is financed by creditors.
Liquidity
Chemours Co reports 4.3 B of total liabilities with total debt to equity ratio (D/E) of 2.94, which may imply that the company relies heavily on debt financing. Chemours has a current ratio of 1.78, which is generally considered normal. Note however, debt could still be an excellent tool for Chemours to invest in growth at high rates of return.

Stock Based Compensation

17.52 Million
Chemours Co (CC) is traded on New York Stock Exchange in USA. It is located in 1007 Market Street, Wilmington, DE, United States, 19801 and employs 6,200 people. Chemours is listed under Diversified Chemicals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a market capitalization of 3.28 B. Chemours is active under Chemicals sector as part of Materials industry. The entity has 149.41 M outstanding shares of which 7.28 M shares are currently sold short in the market by investors with about 4.18 days to cover all shorted shares. Chemours Co reports about 1.1 B in cash with 556 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.73.
Check Chemours Probability Of Bankruptcy
Ownership Allocation
Chemours holds a total of 149.41 Million outstanding shares. The majority of Chemours Co outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Chemours to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Chemours. Please pay attention to any change in the institutional holdings of Chemours Co as this could imply that something significant has changed or is about to change at the company. On September 5, 2023, Representative Michael C Burgess of US Congress acquired $15k to $50k worth of Chemours's common stock.
Check Chemours Ownership Details

Chemours Stock Institutional Holders

InstituionRecorded OnShares
Lsv Asset Management2024-09-30
1.9 M
Norges Bank2024-06-30
1.7 M
Appian Way Asset Management2024-09-30
1.7 M
Luminus Management, Llc2024-09-30
1.6 M
Bank Of New York Mellon Corp2024-06-30
1.6 M
Massachusetts Financial Services Company2024-09-30
1.5 M
American Century Companies Inc2024-09-30
1.5 M
Dimensional Fund Advisors, Inc.2024-09-30
1.5 M
Vision One Management Partners Lp2024-09-30
1.4 M
Fmr Inc2024-09-30
18.1 M
Blackrock Inc2024-06-30
16.3 M
View Chemours Diagnostics

Chemours Historical Income Statement

At present, Chemours' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Reconciled Depreciation is expected to grow to about 330.5 M, whereas Interest Expense is forecasted to decline to about 146.3 M. View More Fundamentals

Chemours Stock Against Markets

Chemours Corporate Directors

Curtis AnastasioIndependent DirectorProfile
Curtis CrawfordIndependent DirectorProfile
Mary CranstonIndependent DirectorProfile
Bradley BellIndependent DirectorProfile
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Diversified Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.65)
Dividend Share
1
Earnings Share
0.5
Revenue Per Share
38.519
Quarterly Revenue Growth
0.009
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.